L
ow-density lipoprotein cholesterol (LDL-C) is a major risk factor for cardiovascular disease, and genetic factors are estimated to account for 40% to 60% of the variation in this trait. [1] [2] [3] Monogenic forms of hypercholesterolemia, caused by mutations in LDLR, APOB, and PCSK9 occur in ≈1 of 250 individuals, 4 whereas the vast majority of cases are multifactorial and polygenic, with single-nucleotide polymorphisms (SNPs) at numerous loci influencing variation in LDL-C identified by combining genome-wide association studies (GWAS) across multiple populations. To date, and despite extensive GWAS and sequencing efforts, only ≈20% of the variation in LDL-C levels is explained by all the common and rare loci identified by sequencing studies and large meta-analyses. [5] [6] [7] Some of the identified loci have been mapped to genes in pathways linked to lipoprotein particle metabolism, whereas other loci map to regions with no apparent biological candidate genes. Uncovering new genes associated with LDL-C levels and the pathways in which these genes reside is of high clinical relevance because such discoveries could reveal new therapeutic targets aimed at LDL-C reduction and cardiovascular disease prevention.
Recent efforts to identify additional lipid-related loci have focused on increasing sample sizes by performing larger and more robust meta-analyses. Studying isolated populations, in which there may be an enrichment of variants that are otherwise rare in outbred populations, offers a complementary strategy. The Amish, a founder population who immigrated to the United States from Europe 14 generations ago, is one such population for whom enrichment of several high penetrance variants influencing serum lipid levels has previously been reported. [8] [9] [10] [11] In this report, we describe a founder haplotype in the Amish that is associated with a 15 mg/ dL elevation in LDL-C levels and provide evidence from association mapping and functional data linking this novel LDL-C-associated locus to a pseudogene associated with a recently discovered apolipoprotein, apolipoprotein O, or APOO.
METHODS
The whole-genome sequencing data generated through the National Heart, Lung and Blood Institute Trans-Omics Precision Medicine (TOPMed) Consortium and used in this study are available on dbGaP (phs000956.v2.p1). Study materials and analytic methods are available on request from the authors for distribution to other researchers for purposes of reproducing the results or replicating the procedure.
We performed an array-wide association of LDL-C levels using the Illumina Cardio-Metabochip (Ilumina) 12 on 1102 Amish subjects who were participants in one of our prior community-based studies focusing on cardiovascular health [13] [14] [15] and replicated the association in an additional 798 Amish subjects. Institutional review board approval was obtained, according to the guidelines of University of Maryland, Baltimore, and informed consent was obtained from all study subjects. To fine map the causative locus on the LDL-C-associated haplotype, we performed genetic association analyses and recombination mapping in a subset of 1094 subjects for whom whole-genome sequence data were available through TOPMed consortium (Expanded Methods in the online-only Data Supplement).
To identify the gene on the associated haplotype driving association, we used wild-type (Tubingen) zebrafish to evaluate the effect of knockdown or overexpression of human chromosome 5q genes (Expanded Methods in the online-only Data Supplement). All procedures described were approved by and in accordance with guidelines of University of Maryland, Baltimore, Institutional Animal Care and Use Committee. Morpholino antisense oligonucleotides (Gene Tools, LLC) were designed and validated to target each ortholog within the chromosome 5 fine-mapped locus. For the genes without identifiable orthologs in zebrafish, we generated expression constructs of human mRNA and injected them into embryos. Zebrafish embryos were cultured until 5 days postfertilization (dpf) and fed either a control or high-cholesterol diet. At 7 dpf we performed in vivo visualization of cholesterol by fluorescent labeling and quantified the amount of vascular plaque formation in the caudal vein (Expanded Methods in the online-only Data Supplement).
To establish APOOP1-specfic expression, we performed reverse transcription polymerase chain reaction (RT-PCR) and sequenced the RT-PCR products to confirm they are APOOP1
Clinical Perspective
What Is New?
• We have identified a novel haplotype influencing low-density lipoprotein cholesterol (LDL-C) levels in the Amish population of Lancaster County, PA, that is associated with an ≈15 mg/dL increase in LDL-C.
• We have linked the high LDL-C phenotype to APOOP1, a transcribed pseudogene, and have provided a possible regulatory link to its parent gene, APOO, that encodes a newly identified apolipoprotein, ApoO.
• We propose that APOOP1 regulates levels of LDL-C in humans, potentially through its interaction with APOO, thus identifying a novel mechanism of lipid homeostasis.
What Are the Clinical Implications?
• Uncovering new genes associated with LDL-C levels and the pathways in which these genes reside is of high clinical relevance because such discoveries could reveal new therapeutic targets aimed at LDL-C reduction and cardiovascular disease prevention.
• These studies implicate a new pathway regulating LDL-C levels that involves APOOP1 and APOO. ORIGINAL RESEARCH ARTICLE transcript-specific and not from amplifying genomic DNA or transcripts from an APOO-related gene (Expanded Methods in the online-only Data Supplement). We also performed in vitro allele-specific transcription assays using an enhancerless pGL3 promoter vector (Promega, E1761) and Huh-7 cells following protocols recommended by Dual-Glo Luciferase Assay System (Promega, E1910). A previously reported liver enhancer served as the positive control. 16 Primer sequences used during cloning sequences containing associated SNPs are available on request. Chromosome conformation capture assays to detect potential promoter and SNP interactions were performed similarly to the protocol described by Hagège et al 17 and Naumova et al 18 using chromosomes from Huh-7 cells and 1 of 3 restriction enzymes: EcoRI, HindIII, or PstI. Detailed protocol and primers used to detect ligated fragments from potential promoter-SNP interactions are available on request.
Statistical Analysis
All genetic association analyses were run using the Mixed Models for Pedigree Analysis software program to account for the relatedness among study subjects. 19 For quantitative RT-PCR (qRT-PCR), samples and controls were run at least in triplicate on a Roche LightCycler 480 instrument and normalized relative to actin expression. The Student t test was used to determine significance. Bonferroni correction was used to adjust for multiple comparisons.
RESULTS

Association of LDL-C With a 3.4 Mb Founder Haplotype
As part of our Amish Complex Disease Research Program, we genotyped the Cardio-Metabochip in 1102 Amish subjects (Table I in the online-only Data Supplement) and tested for association with LDL-C. We observed a significant association between LDL-C and rs17573010, with each copy of the minor allele A (allele frequency, 0.08) associated with a 17.7 mg/dL higher LDL-C (95% confidence interval, 12.4-23.0; P=8.5×10 -11 ) ( Figure I in the online-only Data Supplement). We genotyped this variant in an additional 798 subjects (Table I in the online-only Data Supplement) and, consistent with the Metabochip array analyses, found the G allele of rs17573010 to be associated with higher (8.8 mg/dL; P=0.007) LDL-C levels. In the combined set of 1900 Amish subjects, each copy of the G allele of rs17573010 was associated with a 13.1 mg/dL higher LDL-C level (95% confidence interval, 9.0-17.2; P=9.1×10 -10 ; Table II in the online-only Data Supplement). In contrast, only 5 of the recently identified GWAS loci associated with LDL-C through large metaanalyses have effect sizes >4 mg/dL per allele, including common variants at APOB (4.1 mg/dL per allele), SORT1 (5.6 mg/dL per allele), LDLR (7.0 mg/dL per allele), and APOE (7.1 mg/dL per allele). 20 It is interesting to note that we did not detect an association with this region in our prior GWAS genotyped on the Affymetrix 500K/6 mol/L arrays 8 because rs17573010 is not present on this array and could not be imputed from European imputation reference panels because of its low minor allele frequency (MAF) (0.033 in 1000G EUR [1000 Genome Project European]). Nor has this variant been associated with LDL-C in large general populations reported by others, 5, 7, 21 suggesting it might be marking a novel functional variant through extended linkage disequilibrium, as we have observed for other associations in the Amish. 8, 9 Rs17573010 is an intronic variant that falls within HAVCR1 on chromosome 5q, the gene encoding hepatitis A virus cellular receptor 1. Prior GWAS analyses, most notably the Global Lipids Consortium, 20, 21 identified another SNP in this region (rs6882076) as being associated with LDL-C, albeit with a much smaller effect size, with the C allele of rs6882076 (allele frequency, 0.63) associated with a 1.7 mg/dL lower LDL-C per copy. 20 The estimated effect size of rs6882076 is slightly larger in the Amish (β=5.6 mg/dL lower for the same allele; P=0.01). Rs6882076, which has MAFs of 0.35 and 0.21 in 1000G EUR and Amish, respectively, is located upstream of TIMD4. It is 87 kb away from the peakassociated SNP in the Amish, and the 2 SNPs are not in linkage disequilibrium (r 2 =0.02). This lack of linkage disequilibrium in the Amish implies that rs6882076 and rs17573010 track different causal variants. Although speculative, the most parsimonious interpretation is that both variants regulate the same gene, although we acknowledge that there could be multiple genes in the region influencing variation in LDL-C.
Among the 1901 subjects genotyped for rs17573010 were 7 individuals who were homozygous for the rs17573010 G allele. All 7 had previously been genotyped using the Affymetrix 500K or 6.0 GWAS Array Set (Affymetrix). Examination of these individuals revealed that all were homozygous for ≥6500 SNPs across a ≥4.8 Mb region that included rs17573010, strongly indicative of a founder haplotype that entered the population as a single copy, increased in frequency in the population over time through genetic drift, and then was passed down to both parents of these 7 homozygotes.
To localize the region of association surrounding rs17573010, we performed association analyses of whole-genome sequencing data obtained in a subset of 1094 genotyped Amish subjects recently obtained through the TOPMed consortium. Descriptive characteristics of this cohort are shown in Table I in the onlineonly Data Supplement. Association results of variants in this region with LDL-C are displayed graphically in a zoom plot ( Figure 1A) , with detailed results of the association analyses presented in Table III in the onlineonly Data Supplement. As indicated in these analyses, there was a broad region of association extending over a 3.4 Mb region, from ≈153.8 Mb to 157.2 Mb. The most strongly associated variant in this region is rs193010652 (position chr5:156 410 046), with the minor allele at this locus (MAF=0.076) associated with a 15.7 mg/dL higher LDL-C level; P=4.63×10 -8 , adjusted for age, sex, and APOB R3527Q genotype, a major and common determinant of LDL-C levels in this Amish population 8 (see Expanded Methods in the online-only Data Supplement). The region contains 35 additional variants in high linkage disequilibrium with rs193010652 (r 2 ≥0.80), all showing strong evidence for association with LDL-C levels (5.09×10 -6 <P<4.63×10 -8 ). It is notable that this region carries the signature of a founder haplotype in that nearly all subjects carrying the risk allele at rs193010652 (and rs17573010) also carry the same extended haplotype, presumably inherited from the same founder (see Table III in the online-only Data Supplement).
Narrowing Region of Association Through Recombinant Analysis
In addition to the 7 subjects homozygous for the high LDL haplotype, our sample also included 140 subjects who were heterozygous for this 36-SNP haplotype. Mean LDL-C levels in these individuals were 16.2 mg/ dL higher than in the 862 subjects in the data set not carrying this full risk haplotype ( Figure 1B Table III in the online-only Data Supplement) and one carried by 7 subjects consisting of only 3 SNPs at the telomeric part of the high-risk haplotype (SNPs 34-36, chr5:156 994 242-157 184 358 in Table III in the online-only Data Supplement). In comparison with the 862 subjects not carrying any of the 36 SNPs on the risk haplotype, these subjects had mean LDL-C levels that were 5.9 mg/dL lower and 4.8 mg/dL higher, respectively, suggesting that the causative risk variant falls within a 442-kb region between rs187465743 (chr5:156 186 559) and rs182553698 (chr5:156 629 144); that is, the region containing SNPs 20 to 33 in Table III in the online-only Data Supplement) ( Figure 1B ). There were an additional 3 subjects carrying 17 SNPs at the telomeric part of the high-risk haplotype (SNPs 20-36, chr5:156 186 559 -157 184 358), with LDL-C levels 30.8 mg/dL higher than in subjects without the risk haplotype, also consistent with the localization of the high-risk haplotype to this 442-kb region.
Summary association results for the 14 SNPs comprising the 442-kb haplotype showing peak evidence for association are provided in Table. All SNPs are strongly associated with LDL-C (3.46×10 -6 <P<4.63×10 -8 ). Among these 14 SNPs, which include rs193010652, are 8 with MAF ≤0.01 in 1000G EUR. We speculate that the causative variant likely falls within this set, reasoning that any common SNPs present in the general population would have been well tagged in prior large lipid meta-GWAS studies and thoroughly tested for association with LDL-C in prior meta-analyses. These 8 SNPs are indicated in Figure 1C with an asterisk. The remaining 6 SNPs have minor allele frequencies in 1000G EUR ranging from 0.015 to 0.098. In the Amish the frequencies of these SNPs range from 0.074 to 0.088, and the pairwise r 2 of all SNPs with rs193010652 ranges from 0.90 to 0.99, except for rs142538597, for which its r 2 with rs193010652 is 0.84. The 442-kb high-risk haplotype encodes 7 protein-coding genes (SGCD, TIMD4, HAVCR1, HAVCR2, MED7, ITK, and FAM71B), 4 of which regulate various aspects of immune function (Table IV in the online-only Data Supplement). There are also 2 processed pseudogenes, APOOP1 and PPP1R2P3, that contain multiple stop codons and are not predicted to encode proteins. One of these, APOOP1, is transcriptionally active in liver ( Figure II in the online-only Data Supplement), a tissue highly relevant for cholesterol metabolism. We considered APOOP1 also to be worthy of follow-up analysis because of the important regulatory roles that some pseudogenes are known to play in gene expression, in particular, for their parent genes. [22] [23] [24] It is important to note that the parent gene (APOO) encodes a lipoprotein found in LDL and high-density lipoprotein particles, 25 and overexpression of ApoO in mouse liver leads to altered hepatic fatty acid metabolism.
26
Functional or Regulatory Variants Within the Associated Region
All 14 variants in the narrowed region (which notably include the 8 with MAF <0.01 in 1000G EUR) are located in noncoding regions. Based on functional annotation data provided by ENCODE and Epigenome Roadmap, none of these SNPs are located in sequences with regulatory potential in liver. However, 2 SNPs, rs557762686 and rs17573010, are within sequences annotated as putative enhancers in hepatoma-derived cells, HepG2 (Table V in the online-only Data Supplement). Nevertheless, we assessed whether these 14 noncoding SNPs could assert a regulatory effect on the 9 transcribed genes in this region by using chromosome conformation capture to detect physical proximity and potential interaction between promoters and SNPs via chromatin looping. Of the 126 (14 SNPs×9 promoters) potential interactions, only 4 confirmed chromosome conformation capture products from SNP-containing and promoter-containing restriction fragments were detected: rs143855219 and APOOP1 (Figure 2A through  2D ), rs142557102 with a fragment that contains the HACVR1 promoter, and rs182553698 with both MED7 and a fragment that contains the ITK and FAM71B
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promoters ( Figure III in the online-only Data Supplement). In addition to these functional candidates, SNP rs898956003 resides in a regulatory region predicted to enhance transcription based on histone modification in GM12878 lymphoblastoid cells. When the region containing this SNP was tested in an in vitro reporter assay, we detected a 1.9-fold higher transcription activity for the T allele than for the C allele ( Figure 2E ). In contrast, no such allele-specific activity was found in other regions containing LDL-C-associated SNPs (data not shown). In summary, 4 of the LDL-C-associated SNPs with the strongest statistical evidence for association are located in sequences with regulatory potential and are excellent causal SNP candidates for this association. Adjusted for age, sex, and APOB R3527Q variant, n=1094 whole-genome-sequenced subjects. 1000G EUR indicates 1000 Genome Project European; and LDL-C, low-density lipoprotein cholesterol.
Figure 2. Potential regulatory role of LDL-C associated SNPs.
A, The region containing TIMD4 and APOOP1 is shown with SNP rs143855219 (red star) and possible chromatin looping. B, Coordinates of the 2 EcoRI fragments that are linearly approximately 10 kb apart. C, PCR product demonstrates potential chromatin looping of regions containing rs143855219 and APOOP1 promoter (lane 4). Lanes 1, 2, and 3: no cross-linked DNA, no restriction enzyme, and no DNA ligase controls, respectively. D, The 3C ligation junction sequences were confirmed via sequencing. E, Allele-specific transcription activity of another LDL-C-associated SNP, rs898956003 (green star in A). The region containing the T allele has 1.9-fold higher transcriptional activity than the C allele (P=0.007). 3C indicates chromosome conformation capture; LDL-C, low-density lipoprotein cholesterol; PCR, polymerase chain reaction; and SNP, single-nucleotide polymorphisms.
Functional Screening of Regional Candidate Genes in Zebrafish
Our genetic data and recombinant mapping narrowed the peak region of association with LDL-C levels to a small set of potential causal variants. Yet these studies were unable to identify the causal gene, because reported functions of annotated genes in the associated region offered no obvious biological evidence for association with LDL-C, with the potential exception of APOOP1 (see Table IV in the online-only Data Supplement). To address this further, we turned to a zebrafish system of genetically induced hypercholesterolemia 27 to test the potential contribution of genes in the region to regulation of LDL-C in vivo. We identified zebrafish orthologs for 5 of the 8 candidates in the region: HAVCR1, TIMD4, MED7, ITK, and SGCD (Table VI in the onlineonly Data Supplement). We first verified the expression of each ortholog during zebrafish embryonic and larval stages and confirmed that all were expressed by 5 dpf ( Figure IVA in the online-only Data Supplement). We then designed splice-blocking antisense oligonucleotide morpholinos (MOs) to suppress he expression of each ortholog. Two genes and 1 pseudogene in the region, HAVCR2, FAM71B, and APOOP1 (Table VI in the online-only Data Supplement), did not have identifiable orthologs in the zebrafish. To investigate their function, we generated expression constructs for generation of full-length capped human mRNA for overexpression in zebrafish embryos. We did not examine the other pseudogene, PPP1R2P3, because, unlike APOOP1, it is not transcribed. Each MO or mRNA was injected into 1-to 2-cell stage wild-type embryos that were subsequently grown to 5 dpf. We verified that MO treatment resulted in knockdown of the targeted transcript by qRT-PCR ( Figure IVB and IVC in the online-only Data Supplement) and did not induce off-target toxicity, as detected by quantification of ∆113-p53 expression 28 ( Figure IVD in the online-only Data Supplement). Overexpression of mRNAs was also verified by qRT-PCR ( Figure IVE and IVF in the online-only Data Supplement). At 5 dpf we introduced either a control larval diet (CD) or one supplemented with 4% wt/wt cholesterol (HCD) followed by quantification of LDL-C from homogenates of pooled larvae. We found that on either CD or HCD, no MO or mRNA induced significant upregulation of total LDL-C relative to animals injected with a nonspecific control MO treated with the same diet ( Figure 3A) . It is important to note that we did not see an effect on LDL-C for any of 3 separate MO concentrations or 2 separate mRNA concentrations injected for each gene. The sole exception to this was a significant increase observed by overexpression of APOOP1, which produced an increase in LDL-C on both diets, similar to our positive control, knockdown of ldlr ( Figure 3A ; P<1×10 -11 ). Consistent with this observation, we observed a significant increase in expression of genes involved in cholesterol synthesis, hmgcr and srebp2, in livers dissected from 5 dpf larvae overexpressing APOOP1 mRNA that was not observed on manipulation of other genes ( Figure V in the online-only Data Supplement). To preclude the possibility that overexpression of APOOP1 impacted LDL-C through effects on other genes at the chr5q locus, we examined expression of all other gene orthologs in larvae injected with APOOP1 mRNA. We found no significant changes in the expression of any genes, suggesting that the effects on LDL-C are not mediated by any other genes in the region ( Figure VI in the online-only Data Supplement).
Increased LDL-C is a major risk factor for formation of atherosclerotic plaques and, in zebrafish, is directly associated with the accumulation of oxidized LDL in vascular plaques. 29 To test the potential contribution of any orthologs to vascular plaque formation, we treated MO-or mRNA-injected larvae with CD or HCD supplemented with BODIPY 576/598 C11 allowing for in vivo visualization of cholesterol by fluorescent labeling. 27, 30 On quantification of the average number of fluorescent plaques in a 438.6-μm region of the caudal vein (Figure VII in the online-only Data Supplement), we found that APOOP1 overexpression resulted in an ≈20-fold increase in the average number of vascular plaques observed ( Figure 3B ). This was comparable, albeit less dramatic, to the increase observed with injection of ldlr MO ( Figure 3B ; 7.56 plaques). An increase of this magnitude was not observed for any other MO or mRNA.
Suppression of apoO Expression Increases LDL-C and Plaques
APOOP1 is an expressed pseudogene whose function is unknown. Because pseudogenes can modulate or interfere with parent gene function, we examined the phenotypic relationship between APOOP1 and apoO in zebrafish and tested whether zebrafish apoO could also play a role in cholesterol homeostasis. apoO is present in 2 copies in the zebrafish genome, apoOa and apoOb ( Figure VIII in the online-only Data Supplement). In qRT-PCR analysis of pooled livers dissected from 5 dpf larvae, we identified hepatic expression of both, although apoOb was expressed at significantly higher levels ( Figure IXA , respectively).
DISCUSSION
We have identified a novel association in the Amish with elevated LDL-C on chromosome 5q33. These studies reinforce the value of studying population isolates to map genes for complex traits insofar as the LDL-C association tracks a founder haplotype that likely entered the Amish population on a single founder >14 generations ago and drifted upward in frequency. Thus, this haplotype is tagged by variants that are common in the Amish (MAF=8%) but very rare in non-Amish Europeans. Initial identification of the associated founder haplotype was made possible because the Cardio-Metabochip included a variant that closely tracked this haplotype. In addition to the significant clinical relevance of this haplotype in the Amish, it merits emphasis that its discovery provides a window into the biology of human cholesterol metabolism more generally by implicating a role for APOO in LDL-C regulation, potentially through its mediation by a pseudogene. We also highlight another striking feature of this haplotype made possible ORIGINAL RESEARCH ARTICLE through whole-genome sequencing. That is, despite being associated with ≈15 mg/dL increase in LDL-C, none of the associated variants on the haplotype are linked to a causative variant in exons. Several lines of evidence converge on the pseudogene APOOP1 as the causal gene in the region of association on chromosome 5q33. First, recombination mapping narrowed the region of association to a short list of genes and this region included SNPs demonstrating the strongest evidence for association. Second, this narrowed region also includes a SNP previously associated with LDL-C levels, albeit with a much smaller effect size, but nevertheless suggesting that it could be independently regulating the same causal gene. Finally, functional evaluation of the genes within the narrowed region in zebrafish revealed that overexpression of APOOP1, and reciprocally knocking down apoOA and apoOB, as well, results in significant increases in LDL-C levels and vascular plaque formation.
Our study corroborates a previous large-scale functional examination of 133 genes from 56 loci identified through GWAS of blood lipid-related phenotypes using a cell-based RNA interference screening approach. 31 In that study, small interfering RNA targeting 2 genes, HAVCR1 and TIMD4, at the chromosome 5 locus did not show consistent or significant changes in LDL uptake or in free cholesterol. This is important because these 2 genes are the most proximal to the GWAS association with LDL-C previously reported at this locus, and the failure to detect a consistent phenotype in cellbased studies is consistent with our zebrafish results showing no phenotypic changes in the MO knockdown of these 2 genes. To our knowledge, our study is the first to systematically examine all genes within this locus in a whole animal system using whole-body LDL-C as a phenotypic readout. Furthermore, it is among the few studies to have mapped a noncoding regulatory variant as the most likely causative variant.
Like other processed pseudogenes, APOOP1 lacks introns and contains multiple stop codons. In the past, pseudogenes were believed to be functionless because of their inability to produce proteins. However, several pseudogenes have recently been identified that are not only transcriptionally active, but also capable of influencing the activity of other genes and affecting the phenotype of the organism (reviewed by Pink et al 23 ). 
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Approximately 20% of pseudogenes, especially those that are evolutionarily conserved, are transcribed. 32, 33 APOOP1 is 1 of 5 processed pseudogenes of APOO in the human genome. The other 4 are located on chromosomes 3, 4, 12, and 16. Although APOOP1 is not conserved in mice and zebrafish, it is the only APOO pseudogene that is transcriptionally active in a tissuespecific manner (expression of other 4 pseudogenes are not detected, data not shown), adding further support to its potential functional significance. Pseudogenes interfere with the expression of other genes by several well-defined mechanisms. Pseudogenes can encode for an antisense RNA that inhibits the translation of the parent gene or generate a small interfering RNA that leads to gene silencing. Pseudogenes can also compete for regulatory factors, including transcription factors (via its promoter or other regulatory sites) and microRNA (via the 3ʹ-untranslated region of the noncoding transcript). It is not known how the expressed APOOP1 might alter the expression of APOO. Because APOOP1 is not expressed in peripheral tissues, such as blood, we cannot test whether individuals with different LDL-associated genotypes exhibit differential levels of APOOP1 expression, particularly in liver. However, the 3ʹ-untranslated regions of both APOO and APOOP1 contain microRNA binding sites for miR429/200b, microRNAs that reportedly play a role in diet-induced obesity, nonalcoholic fatty liver disease, and statin responses. [34] [35] [36] Therefore, it is possible that the APOOP1 mRNA influences APOO mRNA stability through microRNA binding and transcript stability, similar to what has been reported for PTEN and its transcribed pseudogene, PTENP1. 37 It is not known if APOOP1 transcripts also interfere with or regulate genes other than APOO, in particular, those regulated by miR-200b/a/429, for which there are predicted target sites in many genes.
There are 2 isoforms of ApoO, a glycosylated and secreted 55-kDa and nonglycosylated 22-kDa mitochondrial protein. APOO mRNA is upregulated in human diabetic heart, 25 and APOO levels are higher in the serum of patients with acute coronary syndrome. 38 small interfering RNA knockdown of APOO in HepG2 cells also alters the expression of genes in fatty acid metabolism and in genes related to the inflammatory response. 39 Also known as MIC26, this lipoprotein is a component of the MICOS complex, which consists of the mitochondrial contact site and cristae organizing system. 40 ApoO overexpression in mouse liver alters the expression of lipid metabolism genes and mitochondrial ultrastructure. 26 Overexpression in mouse hearts impairs mitochondrial function and initiates cardiomyopathy. 41 In contrast, overexpression of apoO in apolipoprotein A-1 transgenic mice does not alter the plasma lipoprotein profile or high-density lipoprotein functions such as protection against LDL oxidation and anti-inflammatory activity on endothelial cells. 42 Although its physiological role is incompletely understood, these studies implicate a critical role for APOO in fatty acid metabolism, mitochondrial function, and inflammatory response.
The functional studies we have performed rest heavily on the use of larval zebrafish as a model for lipid metabolism. The utility of the zebrafish for rapid interrogation of multiple genes makes it uniquely suited to this study where examination of whole-body physiology under the control of multiple different candidate genes allowed us to functionally fine map the human genomic locus. Using this approach, we identified a single candidate at the chromosome 5q locus impacting LDL-C levels. We also capitalized on the transparency of larval zebrafish to directly visualize vascular plaques in vivo, allowing for comprehensive analysis of both LDL-C levels and its consequences for atherosclerotic events. Multiple lines of evidence support the conservation of components of human lipid metabolism in zebrafish. 43 These include major classes of apolipoproteins, 44 and other proteins directly influencing LDL-C and atherogenesis, as well, such as an ortholog of human CETP, which is not found in mice. 43, 45 We have previously demonstrated the power of this combined genetic manipulation and in vivo visualization approach for modeling hypercholesterolemia and atherosclerosis in the context of a wellcharacterized familiar hypercholesterolemia gene, ldlr. 27 Here, we applied this model to identify a novel regulator of human hypercholesterolemia in APOOP1.
Although mouse models have proven to be invaluable for understanding many human phenotypes, they are less suitable for studies requiring rapid genetic screening and in vivo visualization. Moreover, because wild-type mice have a predominantly high-density lipoprotein cholesterol profile and are naturally resistant to atherosclerosis, humanized mouse models are required, such as Ldlr -/-; Apobec1 -/-; Tg-hApoB 46 to produce a lipoprotein profile more closely resembling humans. In zebrafish, however, evidence suggests a substantial LDL-C fraction, especially on introduction of a high-cholesterol diet. 30 Investigating the role of APOOP1 in LDL-C metabolism in mice is also complicated by the fact that there are 3 ApoO pseudogenes in the mouse genome, none of which are syntenic to the human APOOP pseudogenes, and one of which (Apoops, chromosome 13) encodes a noncoding RNA with unknown function. Zebrafish, in contrast, do not have any known expressed pseudogenes to apoo that might interfere with the function of APOOP1 and complicate interpretation of our observations.
In conclusion, these studies implicate a new pathway regulating LDL-C levels that involves APOOP1 and APOO. We propose that a SNP highly enriched in the Amish alters transcription or expression of the nearby APOOP1 pseudogene, which, in turn, interacts with the parent APOO gene, ultimately influencing LDL-C. Based on our zebrafish results, one plausible speculation is that the associated SNP may increase transcription of APOOP1, and increased transcripts may compete for critical binding sites in APOO, thereby downregulating its expression and function. Further studies are necessary to decipher the regulatory interaction between APOOP1 and APOO, which may be apparent only at the level of translation of APOO. Our data, however, support a role for both the pseudogene and APOO itself in regulation of LDL-C, and suggest that manipulation of APOO as a novel therapy for hyperlipidemia.
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